J 2017

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

KRALICKOVA, P., J. KUHNOVA, O. SOUCEK, P. VODAREK, P. ZAK et. al.

Basic information

Original name

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

Authors

KRALICKOVA, P. (203 Czech Republic), J. KUHNOVA (203 Czech Republic), O. SOUCEK (203 Czech Republic), P. VODAREK (203 Czech Republic), P. ZAK (203 Czech Republic), M. SIMKOVIC (203 Czech Republic), M. MOTYCKOVA (203 Czech Republic), L. SMOLEJ (203 Czech Republic), E. MALA (203 Czech Republic), C. ANDRYS (203 Czech Republic), J. KREJSEK (203 Czech Republic) and Vojtěch THON (203 Czech Republic, guarantor, belonging to the institution)

Edition

Journal of Immunology Research, London, Hindawi, 2017, 2314-8861

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.298

RIV identification code

RIV/00216224:14110/17:00099077

Organization unit

Faculty of Medicine

UT WoS

000419035800001

Keywords in English

Pneumococcal Capsular Polysaccharides; Natural Anti-Galactosyl; Humoral Immunodeficiencies

Tags

Tags

International impact, Reviewed
Změněno: 21/3/2018 16:27, Soňa Böhmová

Abstract

V originále

Humoral deficiencies represent a broad group of disorders. The aim of the study was to compare the levels of antibodies against pneumococcal capsular polysaccharides (anti-PCP) and natural anti-galactosyl (anti-Gal) antibodies in (1) patients with chronic lymphocytic leukaemia (CLL), (2) patients with common variable immunodeficiency (CVID), and (3) a healthy population and to explore their diagnostic and prognostic potential. Serum immunoglobulin levels and levels of anti-Gal IgG, IgA, and IgM and anti-PCP IgG and IgG2 were determined in 59 CLL patients, 30 CVID patients, and 67 healthy controls. Levels of IgG, IgA, IgM, anti-Gal IgA, anti-Gal IgM, and anti-PCP IgA were lower in CLL and CVID patients than in healthy controls. Decrease in the levels of IgA, IgM, anti-Gal IgA, and anti-PCP IgA was less pronounced in the CLL group than in the CVID group. IgA decline, anti-Gal IgA, anti-PCP IgA, and anti-PCP IgG2 were negatively correlated with CLL stage. We devise the evaluation of anti-Gal antibodies to be a routine test in humoral immunodeficiency diagnostics, even in cases of immunoglobulin substitution therapy. Significant reductions, mainly in anti-Gal IgA, IgM, and anti-PCP IgA levels, may have prognostic importance in CLL patients.